» Articles » PMID: 32039847

Evidence That Brain-Reactive Autoantibodies Contribute to Chronic Neuronal Internalization of Exogenous Amyloid-β1-42 and Key Cell Surface Proteins During Alzheimer's Disease Pathogenesis

Overview
Publisher Sage Publications
Specialties Geriatrics
Neurology
Date 2020 Feb 11
PMID 32039847
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Blood-brain barrier (BBB) permeability is a recognized early feature of Alzheimer's disease (AD). In the present study, we examined consequences of increased BBB permeability on the development of AD-related pathology by tracking selected leaked plasma components and their interactions with neurons in vivo and in vitro. Histological sections of cortical regions of postmortem AD brains were immunostained to determine the distribution of amyloid-β1-42 (Aβ42), cathepsin D, IgG, GluR2/3, and alpha7 nicotinic acetylcholine receptor (α7nAChR). Results revealed that chronic IgG binding to pyramidal neurons coincided with internalization of Aβ42, IgG, GluR2/3, and α7nAChR as well as lysosomal compartment expansion in these cells in regions of AD pathology. To test possible mechanistic interrelationships of these phenomena, we exposed differentiated SH-SY5Y neuroblastoma cells to exogenous, soluble Aβ42 peptide and serum from AD and control subjects. The rate and extent of Aβ42 internalization in these cells was enhanced by serum containing neuron-binding IgG autoantibodies. This was confirmed by treating cells with individual antibodies specific for α7nAChR, purified IgG from AD or non-AD sera, and sera devoid of IgG, in the presence of 100 nM Aβ42. Initial co-localization of IgG, α7nAChR, and Aβ42 was temporally and spatially linked to early endosomes (Rab11) and later to lysosomes (LAMP-1). Aβ42 internalization was attenuated by treatment with monovalent F(ab) antibody fragments generated from purified IgG from AD serum and then rescued by coupling F(ab) fragments with divalent human anti-Fab. Overall, results suggest that cross-linking of neuron-binding autoantibodies targeting cell surface proteins can accelerate intraneuronal Aβ42 deposition in AD.

Citing Articles

Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Status of Trials and Insights from Preclinical Studies.

Sigurdsson E J Alzheimers Dis. 2024; 101(s1):S129-S140.

PMID: 38427486 PMC: 11587787. DOI: 10.3233/JAD-231238.


A Chronic Increase in Blood-Brain Barrier Permeability Facilitates Intraneuronal Deposition of Exogenous Bloodborne Amyloid-Beta1-42 Peptide in the Brain and Leads to Alzheimer's Disease-Relevant Cognitive Changes in a Mouse Model.

Acharya N, Grossman H, Clifford P, Levin E, Light K, Choi H J Alzheimers Dis. 2024; 98(1):163-186.

PMID: 38393907 PMC: 10977376. DOI: 10.3233/JAD-231028.


Tau-targeting therapies for Alzheimer disease: current status and future directions.

Congdon E, Ji C, Tetlow A, Jiang Y, Sigurdsson E Nat Rev Neurol. 2023; 19(12):715-736.

PMID: 37875627 PMC: 10965012. DOI: 10.1038/s41582-023-00883-2.


Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects.

Loeffler D J Alzheimers Dis Rep. 2023; 7(1):873-899.

PMID: 37662616 PMC: 10473157. DOI: 10.3233/ADR-230025.


Increased plasma and brain immunoglobulin A in Alzheimer's disease is lost in apolipoprotein E ε4 carriers.

Poceviciute D, Nunez-Diaz C, Roth B, Janelidze S, Giannisis A, Hansson O Alzheimers Res Ther. 2022; 14(1):117.

PMID: 36008818 PMC: 9414424. DOI: 10.1186/s13195-022-01062-z.


References
1.
Dandrea M, Nagele R, Wang H, Peterson P, Lee D . Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology. 2001; 38(2):120-34. DOI: 10.1046/j.1365-2559.2001.01082.x. View

2.
Acharya N, Levin E, Clifford P, Han M, Tourtellotte R, Chamberlain D . Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib. J Alzheimers Dis. 2013; 35(1):179-98. DOI: 10.3233/JAD-122254. View

3.
Levin E, Acharya N, Han M, Zavareh S, Sedeyn J, Venkataraman V . Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown. Brain Res. 2010; 1345:221-32. DOI: 10.1016/j.brainres.2010.05.038. View

4.
Nagele E, Han M, DeMarshall C, Belinka B, Nagele R . Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One. 2011; 6(8):e23112. PMC: 3149629. DOI: 10.1371/journal.pone.0023112. View

5.
Sedeyn J, Wu H, Hobbs R, Levin E, Nagele R, Venkataraman V . Histamine Induces Alzheimer's Disease-Like Blood Brain Barrier Breach and Local Cellular Responses in Mouse Brain Organotypic Cultures. Biomed Res Int. 2015; 2015:937148. PMC: 4677161. DOI: 10.1155/2015/937148. View